Καναδάς - Αγγλικά - Health Canada

eli lilly canada inc - insulin glargine - solution - 100unit - insulin glargine 100unit - insulins

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

remedyrepack inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. pregnancy category b. all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. careful monitoring of glucose control is essential in these patients. therefore, female patients should be advised to tell

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

insulin lispro -

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg, overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg, overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; 0-3% overage) - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; 0-3% overage) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin - human -

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml;   - solution for injection - 100 u/ml - active: insulin lispro 100 u/ml   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.